PMC:7195088 / 15837-16158 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"656","span":{"begin":57,"end":65},"obj":"Species"},{"id":"737","span":{"begin":14,"end":19},"obj":"Chemical"},{"id":"738","span":{"begin":20,"end":29},"obj":"Chemical"},{"id":"739","span":{"begin":34,"end":53},"obj":"Chemical"},{"id":"740","span":{"begin":230,"end":236},"obj":"Chemical"},{"id":"741","span":{"begin":259,"end":263},"obj":"Chemical"},{"id":"909","span":{"begin":81,"end":89},"obj":"Disease"}],"attributes":[{"id":"A656","pred":"tao:has_database_id","subj":"656","obj":"Tax:9606"},{"id":"A738","pred":"tao:has_database_id","subj":"738","obj":"MESH:D019438"},{"id":"A739","pred":"tao:has_database_id","subj":"739","obj":"MESH:C558899"},{"id":"A740","pred":"tao:has_database_id","subj":"740","obj":"MESH:D010100"},{"id":"A909","pred":"tao:has_database_id","subj":"909","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Comparison of ASC09/ritonavir vs. lopinavir/ritonavir in patients with confirmed COVID-19 pneumoniae. Open-label RCT (NCT04261907, not yet recruiting). Primary endpoint: adverse outcome at day 14 (composite of Spo 2 ≤ 93% without oxygen supplementation, PaO2/FiO2 ≤ 300 mm Hg or respiratory rate ≥ 30 breaths per minute)."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T15","span":{"begin":90,"end":100},"obj":"Phenotype"}],"attributes":[{"id":"A15","pred":"hp_id","subj":"T15","obj":"http://purl.obolibrary.org/obo/HP_0002090"}],"text":"Comparison of ASC09/ritonavir vs. lopinavir/ritonavir in patients with confirmed COVID-19 pneumoniae. Open-label RCT (NCT04261907, not yet recruiting). Primary endpoint: adverse outcome at day 14 (composite of Spo 2 ≤ 93% without oxygen supplementation, PaO2/FiO2 ≤ 300 mm Hg or respiratory rate ≥ 30 breaths per minute)."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T77","span":{"begin":81,"end":89},"obj":"Disease"},{"id":"T78","span":{"begin":90,"end":100},"obj":"Disease"}],"attributes":[{"id":"A77","pred":"mondo_id","subj":"T77","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A78","pred":"mondo_id","subj":"T78","obj":"http://purl.obolibrary.org/obo/MONDO_0005249"}],"text":"Comparison of ASC09/ritonavir vs. lopinavir/ritonavir in patients with confirmed COVID-19 pneumoniae. Open-label RCT (NCT04261907, not yet recruiting). Primary endpoint: adverse outcome at day 14 (composite of Spo 2 ≤ 93% without oxygen supplementation, PaO2/FiO2 ≤ 300 mm Hg or respiratory rate ≥ 30 breaths per minute)."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T60","span":{"begin":107,"end":112},"obj":"http://purl.obolibrary.org/obo/CLO_0007225"},{"id":"T61","span":{"begin":214,"end":220},"obj":"http://purl.obolibrary.org/obo/CLO_0001230"},{"id":"T62","span":{"begin":214,"end":220},"obj":"http://purl.obolibrary.org/obo/CLO_0037237"},{"id":"T63","span":{"begin":214,"end":220},"obj":"http://purl.obolibrary.org/obo/CLO_0050903"},{"id":"T64","span":{"begin":214,"end":220},"obj":"http://purl.obolibrary.org/obo/CLO_0054249"},{"id":"T65","span":{"begin":214,"end":220},"obj":"http://purl.obolibrary.org/obo/CLO_0054250"},{"id":"T66","span":{"begin":214,"end":220},"obj":"http://purl.obolibrary.org/obo/CLO_0054251"},{"id":"T67","span":{"begin":214,"end":220},"obj":"http://purl.obolibrary.org/obo/CLO_0054252"}],"text":"Comparison of ASC09/ritonavir vs. lopinavir/ritonavir in patients with confirmed COVID-19 pneumoniae. Open-label RCT (NCT04261907, not yet recruiting). Primary endpoint: adverse outcome at day 14 (composite of Spo 2 ≤ 93% without oxygen supplementation, PaO2/FiO2 ≤ 300 mm Hg or respiratory rate ≥ 30 breaths per minute)."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T92","span":{"begin":20,"end":29},"obj":"Chemical"},{"id":"T93","span":{"begin":34,"end":53},"obj":"Chemical"},{"id":"T94","span":{"begin":34,"end":43},"obj":"Chemical"},{"id":"T95","span":{"begin":44,"end":53},"obj":"Chemical"},{"id":"T96","span":{"begin":107,"end":112},"obj":"Chemical"},{"id":"T97","span":{"begin":230,"end":236},"obj":"Chemical"},{"id":"T98","span":{"begin":273,"end":275},"obj":"Chemical"}],"attributes":[{"id":"A92","pred":"chebi_id","subj":"T92","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A93","pred":"chebi_id","subj":"T93","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"},{"id":"A94","pred":"chebi_id","subj":"T94","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A95","pred":"chebi_id","subj":"T95","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A96","pred":"chebi_id","subj":"T96","obj":"http://purl.obolibrary.org/obo/CHEBI_35209"},{"id":"A97","pred":"chebi_id","subj":"T97","obj":"http://purl.obolibrary.org/obo/CHEBI_25805"},{"id":"A98","pred":"chebi_id","subj":"T98","obj":"http://purl.obolibrary.org/obo/CHEBI_16170"},{"id":"A99","pred":"chebi_id","subj":"T98","obj":"http://purl.obolibrary.org/obo/CHEBI_25195"}],"text":"Comparison of ASC09/ritonavir vs. lopinavir/ritonavir in patients with confirmed COVID-19 pneumoniae. Open-label RCT (NCT04261907, not yet recruiting). Primary endpoint: adverse outcome at day 14 (composite of Spo 2 ≤ 93% without oxygen supplementation, PaO2/FiO2 ≤ 300 mm Hg or respiratory rate ≥ 30 breaths per minute)."}

{"project":"LitCovid-sentences","denotations":[{"id":"T100","span":{"begin":102,"end":151},"obj":"Sentence"},{"id":"T101","span":{"begin":152,"end":321},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Comparison of ASC09/ritonavir vs. lopinavir/ritonavir in patients with confirmed COVID-19 pneumoniae. Open-label RCT (NCT04261907, not yet recruiting). Primary endpoint: adverse outcome at day 14 (composite of Spo 2 ≤ 93% without oxygen supplementation, PaO2/FiO2 ≤ 300 mm Hg or respiratory rate ≥ 30 breaths per minute)."}